Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/128109
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Muñoz-Torrero López-Ibarra, Diego | - |
dc.contributor.author | Pérez Areales, Francisco Javier | - |
dc.date.accessioned | 2019-02-11T08:40:00Z | - |
dc.date.available | 2019-02-11T08:40:00Z | - |
dc.date.issued | 2018 | - |
dc.identifier.uri | http://hdl.handle.net/2445/128109 | - |
dc.description | Podeu consultar el llibre complet a: http://hdl.handle.net/2445/128014 | ca |
dc.description.abstract | Alzheimer’s disease (AD) is the main neurodegenerative disorder worldwide. Its pathogenesis involves a network where various mechanisms are interconnected. This complex pathological network makes it extremely challenging to find an efficacious treatment. Herein, we give an overview on the design of the so-called multi-target-directed ligands, i.e. compounds that concurrently hit several key pathogenic factors within the network, as a realistic option to tackle AD, with a particular emphasis on some structural classes of multitarget hybrids recently developed in our group. | ca |
dc.format.extent | 16 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | ca |
dc.publisher | Research Signpost | ca |
dc.relation.isformatof | Reproducció del capítol del llibre publicat a: http://www.trnres.com/ebookcontents.php?id=287 | - |
dc.relation.ispartof | Recent Advances in Pharmaceutical Sciences VIII, 2018, Research Signpost. Editors: Diego Muñoz-Torrero, Yolanda Cajal and Joan Maria Llobet. ISBN: 978-81-308-0579-5. Chapter 3, p. 43-58 | - |
dc.relation.uri | http://hdl.handle.net/2445/128014 | - |
dc.relation.uri | http://hdl.handle.net/2445/115549 | - |
dc.rights | (c) Research Signpost, 2018 | - |
dc.rights.uri | http://creativecommons.org/publicdomain/zero/1.0/ | * |
dc.source | Llibres / Capítols de llibre (Farmacologia, Toxicologia i Química Terapèutica) | - |
dc.subject.classification | Desenvolupament de medicaments | - |
dc.subject.classification | Malaltia d'Alzheimer | - |
dc.subject.classification | Química farmacèutica | - |
dc.subject.other | Drug development | eng |
dc.subject.other | Alzheimer's disease | eng |
dc.subject.other | Pharmaceutical chemistry | - |
dc.title | Development of hybrid compounds to tackle Alzheimer’s disease | ca |
dc.type | info:eu-repo/semantics/bookPart | ca |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 310893 | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | ca |
Appears in Collections: | Llibres / Capítols de llibre (Farmacologia, Toxicologia i Química Terapèutica) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
T_1548756197munoz 3.pdf | 1.5 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License